РАПАКИ Алан Р. (US),РУБИНЧИК Вэлери (CA),КЬЕЛБОТН Чарлз Р. (CA)
申请号：
RU2011138947/14
公开号：
RU2011138947A
申请日:
2010.02.23
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. Lakrimalny implant inserted into the lacrimal canaliculus and comprising a housing including first and second portions and extending from the proximal end of the first part to the distal end of the second part the first proximal end portion defining a longitudinal axis and having a proximal locking protrusion protruding transversely at different distances along the rim the distal end of the second part defining a longitudinal axis of the distal wherein the implant body is configured such that when it is implanted in a lacrimal Canadian proximal axis and the distal axis intersect at an angle to abut at least a portion of the implant body in at least a portion of the lacrimal canaliculus located at the bend of the tubule or farther from it.2. Lakrimalny implant according to claim 1, wherein the proximal end portion of the first locking projection projects transversely outwardly at a different lateral distance along a circle and tapers to the outer diameter of the distal end of the first part.3. Lakrimalny implant according to claim 2, comprising gripping protrusion protruding at least partially from the proximal end of the first portion and adapted to be positioned opposite the tear point or close to it when implanted implant body wherein the perimeter of the proximal end portion of the first locking projection is approximately equal perimeter gripping protrusion.4. Lakrimalny implant according to claim 2, wherein the proximal end portion of the first locking projection bulges outward in opposite directions on opposite first and second sides, without protruding outwardly from the outer diameter at the opposite third and fourth sides.Lakrimalny 5. The implant of claim 1 further comprising one or more therapeutic agents.6. Lakrimalny implant according to claim 5, wherein the one or more therapeutic agents in the drug insert located at least partially located in the first portion, the drug insert adapted to provide sustained release of one or more therapeutic agents.7
